Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Water and aqueous buffers | Near neutral pH |
| Storage temperature | Minus 20 to minus 80 C | Long-term, lyophilized |
| Analytical method | RP-HPLC | Purity assessment |
| Typical purity | Greater than 95 percent | Research-grade material |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Long, however, did not publish his experience until 1849, thereby denying himself much of the credit he deserved. With the beginnings of modern medicine the stage was set for physicians and surgeons to build a paradigm in which anesthesia became useful. On 10 December 1844, Gardner Quincy Colton held a public demonstration of nitrous oxide in Hartford, Connecticut. One of the participants, Samuel A. Cooley, sustained a significant injury to his leg while under the influence of nitrous oxide without noticing the injury. Horace Wells, a Connecticut dentist present in the audience that day, immediately seized upon the significance of this apparent analgesic effect of nitrous oxide. The following day, Wells underwent a painless dental extraction while under the influence of nitrous oxide administered by Colton. Wells then began to administer nitrous oxide to his patients, successfully performing several dental extractions over the next couple of weeks. William T. G. Morton, another New England dentist, was a former student and then-current business partner of Wells. He was also a former acquaintance and classmate of William Edward Clarke (the two had attended undergraduate school together in Rochester, New York). Morton arranged for Wells to demonstrate his technique for dental extraction under nitrous oxide general anesthesia at Massachusetts General Hospital, in conjunction with the prominent surgeon John Collins Warren. This demonstration, which took place on 20 January 1845, ended in failure when the patient cried out in pain in the middle of the operation.
Bloch's was a philosophy that could hold its head high before the most advanced literature; a philosophy that was not calibrated to the abominable resignation of methodology ... I took this motif so much as my own that I do not believe I have ever written anything without reference to it, either implicit or explicit.Adorno's intellectual non-conformism was also shaped by the repugnance he felt towards the nationalism that swept through the Reich during the First World War. Along with future collaborators Walter Benjamin, Max Horkheimer, and Ernst Bloch, Adorno was profoundly disillusioned by the ease with which Germany's intellectual and spiritual leaders—among them Max Weber, Max Scheler and Georg Simmel, as well as his friend Siegfried Kracauer—came out in support of the war. The younger generation's distrust for traditional knowledge arose from how this tradition had discredited itself. Over time, Oscar Wiesengrund's firm established close professional and personal ties with the factory of Karplus & Herzberger in Berlin. The eldest daughter of the Karplus family, Margarete, or Gretel, moved into the intellectual circles of Berlin, where she became acquainted with Benjamin, Bertolt Brecht, and Bloch, each of whom Adorno would become familiar with during the mid-1920s. After fourteen years, Gretel Karplus and Adorno were married in 1937.
=== MeSH D12.644.548 – peptide hormones === MeSH D12.644.548.009 – activins MeSH D12.644.548.009.500 – inhibin-beta subunits MeSH D12.644.548.014 – adiponectin MeSH D12.644.548.020 – atrial natriuretic factor MeSH D12.644.548.100 – bombesin MeSH D12.644.548.150 – calcitonin MeSH D12.644.548.200 – corticotropin-releasing hormone MeSH D12.644.548.275 – gastric inhibitory polypeptide MeSH D12.644.548.280 – gastrins MeSH D12.644.548.343 – glucagon precursors MeSH D12.644.548.343.249 – enteroglucagons MeSH D12.644.548.343.249.500 – glucagon-like peptide 1 MeSH D12.644.548.343.500 – glucagon MeSH D12.644.548.387 – inhibins MeSH D12.644.548.387.500 – inhibin-beta subunits MeSH D12.644.548.393 – insulin MeSH D12.644.548.393.408 – insulin, isophane MeSH D12.644.548.393.532 – insulin, long-acting MeSH D12.644.548.393.788 – proinsulin MeSH D12.644.548.393.788.250 – c-peptide MeSH D12.644.548.400 – leptin MeSH D12.644.548.500 – motilin MeSH D12.644.548.560 – msh release-inhibiting hormone MeSH D12.644.548.580 – msh-releasing hormone MeSH D12.644.548.585 – natriuretic peptide, c-type MeSH D12.644.548.587 – pancreatic polypeptide MeSH D12.644.548.588 – parathyroid hormone-related protein MeSH D12.644.548.590 – parathyroid hormone MeSH D12.644.548.590.850 – teriparatide MeSH D12.644.548.592 – peptide phi MeSH D12.644.548.595 – peptide yy MeSH D12.644.548.600 – pituitary hormone release inhibiting hormones MeSH D12.644.548.620 – pituitary hormone-releasing hormones MeSH D12.644.548.691 – pituitary hormones MeSH D12.644.548.691.525 – pituitary hormones, anterior MeSH D12.644.548.691.525.343 – gonadotropins, pituitary MeSH D12.644.548.691.525.343.288 – follicle stimulating hormone MeSH D12.644.548.691.525.343.288.500 – follicle stimulating hormone, beta subunit MeSH D12.644.548.691.525.343.288.750 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.343.463 – luteinizing hormone MeSH D12.644.548.691.525.343.463.249 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.343.463.500 – luteinizing hormone, beta subunit MeSH D12.644.548.691.525.343.583 – menotropins MeSH D12.644.548.691.525.343.583.500 – urofollitropin MeSH D12.644.548.691.525.425 – growth hormone MeSH D12.644.548.691.525.425.875 – human growth hormone MeSH D12.644.548.691.525.525 – prolactin MeSH D12.644.548.691.525.690 – pro-opiomelanocortin MeSH D12.644.548.691.525.690.130 – corticotropin MeSH D12.644.548.691.525.690.130.050 – alpha-msh MeSH D12.644.548.691.525.690.130.200 – cosyntropin MeSH D12.644.548.691.525.690.480 – lipotropin MeSH D12.644.548.691.525.690.583 – melanocyte-stimulating hormones MeSH D12.644.548.691.525.690.583.050 – alpha-msh MeSH D12.644.548.691.525.690.583.075 – beta-msh MeSH D12.644.548.691.525.690.583.115 – gamma-msh MeSH D12.644.548.691.525.883 – thyrotropin MeSH D12.644.548.691.525.883.249 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.883.500 – thyrotropin, beta subunit MeSH D12.644.548.691.692 – pituitary hormones, posterior MeSH D12.644.548.691.692.433 – oxytocin MeSH D12.644.548.691.692.781 – vasopressins MeSH D12.644.548.691.692.781.100 – argipressin MeSH D12.644.548.691.692.781.100.250 – deamino arginine vasopressin MeSH D12.644.548.691.692.781.400 – lypressin MeSH D12.644.548.691.692.781.400.350 – felypressin MeSH D12.644.548.691.692.781.700 – ornipressin MeSH D12.644.548.691.692.881 – vasotocin MeSH D12.644.548.726 – placental hormones MeSH D12.644.548.726.367 – chorionic gonadotropin MeSH D12.644.548.726.367.125 – chorionic gonadotropin, beta subunit, human MeSH D12.644.548.726.367.562 – glycoprotein hormones, alpha subunit MeSH D12.644.548.726.451 – gonadotropins, equine MeSH D12.644.548.726.692 – placental lactogen MeSH D12.644.548.762 – relaxin MeSH D12.644.548.786 – resistin MeSH D12.644.548.810 – secretin MeSH D12.644.548.857 – somatostatin MeSH D12.644.548.869 – thymosin MeSH D12.644.548.905 – urotensins MeSH D12.644.548.952 – vasoactive intestinal peptide
Sources: en.wikipedia.org
== Food preparation == Archaeological excavation of ceramic assemblages, pertaining to the Inca, reveal the variety of vessels used in their cuisine. In many excavations, of the ceramic assemblages found, about one tenth tend to be vessels. Ollas were used for cooking, boiling, and stewing, and were essential to Inca cuisine preparation. Ollas were used frequently, since boiling was one of the most repeated food preparation techniques. The vessel is characterized by its wide mouth, with a variety of bases, including the conical-based, round-bottomed, and pedestal-based forms. The Moche, a civilization inhabiting the region before the Inca, elevated olla production by implementing the paddle-and-anvil technique. This technique involved a stone being held on the inside of the vessel, while a wooden paddle was used to form the outside's shape. The practice of the paddle-and-anvil technique added an artistic aspect to the creation of ollas, as the technique provided plenty of flexibility and variation for designing unique vessels. This practice continued into the Inca time period. Other ceramic vessels could be associated with chicha production, which involves its own intricate system of preparation. El Shincal, located in the Argentinian province of Catamarcas, is a chicha production site observed in archaeological studies. Archaeologists have interpreted the purpose of the site as a location that solely caters to feasts and ceremonial events, rather than as a place of permanent settlement.
Naturally occurring barium (56Ba) is a mix of six stable isotopes and one very long-lived radioactive primordial isotope, barium-130, identified as being unstable by geochemical means (from analysis of the presence of its daughter xenon-130 in rocks) in 2001, presumably decaying by double electron capture with a half-life of (0.5–2.7)×1021 years (about 1011 times the age of the universe). The two measurements are discordant; the above reflects the total range, the value in the table below is a crude average. With the total range of mass numbers known 114 to 154, there are thirty-three known radioisotopes in addition to 130Ba. The longest-lived of these is 133Ba, which has a half-life of 10.538 years; all others have half-lives shorter than two weeks. The longest-lived isomers are 133mBa at 38.90 hours and 135m1Ba at 28.11 hours. The analogous 137m1Ba (half-life 2.552 minutes) occurs in the decay of the common fission product caesium-137. Barium-114 is theorized to undergo cluster decay, emitting a nucleus of stable 12C to produce 102Sn. This decay has not been observed, with only an upper limit on the branching ratio of such decay (0.0034%).
=== New Zealand in 1998 === In 1998 he walked from Cape Reinga in the North Island, to Bluff, at the southern tip of New Zealand; a distance of 1,500 miles (2,400 km). On the journey he walked through the active volcano at White Island, experienced earthquakes up to 4.9 on the Richter Scale, clambered over glaciers, swam with seals and reported on conservation biology projects involving endangered species. Information from the journey was posted on the Internet for schoolchildren in the U.S. via the Scholastic Corporation Scholastic Network. In December 2010 Skinner completed a book about the journey and conservation biology, New Zealand – 1500 miles on foot through – The Land of the Long White Cloud on an Internet website. In 1999 he obtained a PGCE (Postgraduate Certificate in Education) from Canterbury Christ Church University in Canterbury, England. In 2000 he worked as a secondary school science teacher at St. Edmund's School in Dover, teaching 11 to 16-year-olds. In 2001 he worked as a volunteer at a wildlife park, working on enrichment activities for animals. From 2001 until 2003 he worked part-time at a post office. During this time, he also taught science to primary school children, in a 'Link-Scientist' scheme run by the pharmaceutical company Pfizer, and took care of his son. In 2003 his mother died from pancreatic cancer, at the age of 59. This prompted him to write the story of the 6,000 miles (9,700 km) journey across Britain and America.
On February 19, 2019, Pritzker signed into law a bill that raises the state minimum wage to $15 an hour by 2025, making Illinois the fifth state in the nation and first state in the Midwest to do so. The bill includes a tax credit for small businesses to help them deal with higher costs of labor and maintains the ability of restaurant owners to count tips toward pay. On April 12, 2019, Pritzker signed the Collective Bargaining Freedom Act, which protects the right of employers, employees, and their labor organizations to collectively bargain, ensuring that Illinois complies with the National Labor Relations Act. On May 17, 2019, Pritzker signed legislation to help workers exposed to toxic substances. In July 2019, Pritzker signed House Bill 2028, which passed both the Senate and House of Illinois unanimously. This bill doubles the compensation rate for families of police officers and firefighters killed in the line of duty from $10,000 to $20,000. On March 13, 2023, Pritzker signed the Paid Leave for All Workers Act, which requires employers to give employees at least an hour of paid leave for every 40 hours of work, up to 40 hours per year, which employees can use for any reason. It went into effect in 2024.
Sources: en.wikipedia.org
Nutt has published studies praising the potential of pagoclone which were financed by Indevus which was seeking funding for a possible production of the compound. The long-term safety of pagoclone has not been assessed. The abuse potential of pagoclone has been assessed as being similar to, or slightly less than that of diazepam and it would also be expected to be somewhat safer due to its relatively weaker sedative effects, but development of pagoclone as a commercial drug would still be unlikely due to concerns about abuse. Pagoclone was trialed as a drug to improve speech fluency as a treatment for stuttering, but research for this application was discontinued following disappointing results in Phase II clinical trials.
== Chemistry == Prednisone is a synthetic pregnane corticosteroid and derivative of cortisone and is also known as δ1-cortisone or 1,2-dehydrocortisone or as 17α,21-dihydroxypregna-1,4-diene-3,11,20-trione.
RuBisCO is one of many enzymes in the Calvin cycle. When RuBisCO facilitates the attack of CO2 at the C2 carbon of RuBP and subsequent bond cleavage between the C3 and C2 carbon, 2 molecules of glycerate-3-phosphate are formed. The conversion involves these steps: enolisation, carboxylation, hydration, C-C bond cleavage, and protonation.
Sources: en.wikipedia.org
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.
Repeated temperature cycling can promote aggregation and peptide degradation. Dividing material into single-use aliquots limits this risk.
Mass spectrometry is commonly used to confirm molecular mass and detect structural modifications. It is often paired with chromatographic purity assessment.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.